Intracardiac Devices for Stroke Prevention: The Heart Brain Team
|
|
- Chester Washington
- 5 years ago
- Views:
Transcription
1 Intracardiac Devices for Stroke Prevention: The Heart Brain Team CREIGHTON W. DON, MD, PHD ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR, INTERVENTIONAL AND STRUCTURAL HEART FELLOWSHIPS DIVISION OF CARDIOLOGY UNIVERSITY OF WASHINGTON
2
3 The heart and brain Heart attacks Brain attacks PCI for acute MI Mechanical thrombectomy for stroke
4 Where do strokes come from? Cardioembolic strokes 20% of all stroke Atrial fibrillation atrial clots LV dysfunction LV clots Valvular disease Venous clot, passing through heart PFO (Patent foramen ovale)
5 Devices for stroke reduction Left Atrial Appendage Closure Patent Foramen Ovale Closure
6 Atrial Fibrillation and Stroke
7 Atrial Fibrillation Prevalence Prevalence 2.7 to 6.1 million in US Underestimated Subclinical afib 10-30% patients 65 yrs Ischemic stroke HR 2.50 ~20% for patients 80 years Mozaffarian D. Heart Disease and Stroke Statistics 2016 Update. Circulation. 2016
8 Atrial fibrillation and Stroke Risk Overall 4 to 5 fold increase in the risk for stroke Similar for paroxysmal, persistent, permanent Risk factor for stroke severity Age Prevalence Proportion of attributable risk Relative Risk Goldstein LB. Stroke Feb;42(2): Lin HJ. Stroke. 1996;27:
9 Proportional attributable risk: AFIB 30.0% Men Women 25.0% Atrial Fibrillation 20.0% 15.0% 10.0% 5.0% 0.0% Mozaffarian D. Heart Disease and Stroke Statistics 2016 Update. Circulation. 2016
10 Left Atrial Appendage and Stroke
11 70 year old with stroke HTN Dyslipidemia Amyloidosis Renal Insufficiency Myocardial Infarction LV dysfunction EF 45% Atrial fibrillation
12 Mechanisms of Stroke with Atrial Fibrillation Stasis of blood Spontaneous echo contrast Increased thrombus with larger left atria Left atrial appendage anatomy LAA Courtesy Mark Reisman. Seattle Science Foundation
13 Thrombus location Approximately 75% of embolic events in afib are from atrial thrombi Rheumatic atrial fibrillation Thrombus in LA appendage: 57% Non-rheumatic atrial fibrillation Thrombus in LA appendage: 91% Study N LA Appendage LA chamber TEE TEE Autopsy TEE TEE TEE + surgery TEE (SPAF 3) TEE TEE Total Blackshear JL. Annals of Thoracic Surg
14 Left atrial appendage anatomy and risk for embolism Morphology Number of lobes Shape of lobes Volume Tribeculation Flow velocity
15 Left Atrial Appendage Anatomy Chicken Wing Windsock Cactus Cauliflower Don C et al. Catheter Interventions for Structural Heart Disease
16 LAA Morphology and Stroke Risk CHADS2 Stroke risk 1yr to 1.7% to 2.2% to 7.9% Goldstein LB.Stroke Di Baise L. JACC
17 Atrial Fibrillation and Anticoagulation
18 Anticoagulation and stroke reduction Treatment Placebo 8.0% 7.4% Stroke Incidence 6.0% 4.0% 2.0% 2.3% 3.6% 6.3% 2.9% 3.1% 3.0% 2.3% 2.6% 2.2% 4.2% 4.5% 0.0% SPAF Investigators. Circulation. 1996; Patel MR. NEJM. 2011; Granger CB. NEJM. 2011; Giugliano RP. NEJM Don C et al. Catheter Interventions for Structural Heart Disease Adapted from Go AS et al. JAMA 2003.
19 Undertreatment causes strokes
20 Difficult to manage 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 19% 48% % of Patients Within INR Range 1 54% 33% 37% 9% 11% % 27% Group Health Cooperative Kaiser Permanente SC ATRIA Below INR Range Within Range Above Range INR 3+ 44% of bleeding events INR % of embolic events Warfarin is #1 cause for emergency hospitalizations due to adverse drug events 1 Glazer NL, Arch Intern Med (2007) 2 Shen AY, J Am Coll Cardiol (2007) 3 Go AS, JAMA (2003) 4 Rudnitz ME, Annals of Int Med (2007)
21 Left atrial appendage closure Warfarin Use by CHADS 2 Score Medicare claims data, AF Patients Using Warfarin 100% 80% 60% 40% p < (n=27,164) 20% 0% CHADS 2 Score Piccini, et al.. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012;9: J Thromb and Haemostasis.
22 Underutilization of anticoagulation 100% 90% Anticoagulant Use in Patients with NVAF and CHADS % 70% 60% 50% 40% 30% 20% Total on Oral Anticoagulation Warfarin DOACs 10% 0% 2011 Q Q Q Q Q Q Q Q4 n=25719 n=29194 n=31582 n=36490 n=67102 n=70667 n=70320 n=71396 Results from the NCDR PINNACLE Registry 1 1. Jani, et al. Uptake of Novel Oral Anticoagulants in Patients with Non-Valvular and Valvular Atrial Fibrillation: Results from the NCDR-Pinnacle Registry. ACC 2014
23 DOAC discontinuation clinical trials Treatment Study Drug Discontinuation Rate Major Bleeding (rate/year) Rivaroxaban 1 24% 3.6% Apixaban 2 25% 2.1% Dabigatran 3 (150 mg) Edoxaban 4 (60 mg / 30 mg) 21% 3.1% 33 % / 34% 2.8% / 1.6% Warfarin % % 1. Connolly, S. NEJM 2009; 361: Patel, M. NEJM 2011; 365: yrs follow-up, ITT 3. Granger, C NEJM 2011; 365: yrs follow-up, 4. Giugliano, R. NEJM 2013; 369(22): yrs follow-up.
24 DOAC discontinuation real world Martinez C, et al. Therapy Persistence in Newly Diagnosed Non-Valvular Atrial Fibrillation Treated with Warfarin or NOAC. A Cohort Study. Thromb Haemost Dec 22;115(1):31-9.
25 LAA LAA Closure and Stroke Prevention
26 Watchman LAA closure device 160 Micron Membrane Percutaneous femoral venous Sizes: 21, 24, 27, 30, 33 mm diameter Transseptal puncture TEE guidance min procedure Overnight hospitalization Nitinol frame with Anchors
27 Left Atrial Appendage Closure TEE planning
28 Left Atrial Appendage Closure
29 Left Atrial Appendage Closure
30 Left Atrial Appendage Closure
31 Left Atrial Appendage Closure Canine model 30 day Canine model 45 day Human pathology - 9 months (non-device related death)
32 PROTECT-AF Trial Randomized study of LAAO (Watchman) vs. Warfarin 2:1 707 Patients with CHADS2 1 Mean 2.2 to 2.3 Patients randomized to Watchman Warfarin for 45 days ASA + Clopidogrel 6 months ASA indefinitely
33 Left atrial appendage closure PROTECT AF: 4-year results 16.0% 14.0% 12.0% * 13.9% Device Warfarin * 13.0% 11.1% % Patients 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% 8.4% 8.2% 5.6% 5.2% 4.1% 4.1% 4.5% 1.7% 0.6% 3.7% 9.0% Reddy, VY et al. JAMA. 2014;312(19):
34 PROTECT-AF Trial: Mortality Reddy, VY et al. JAMA. 2014;312(19):
35 Left atrial appendage closure PROTECT AF: 4-year results Reddy, VY et al. JAMA. 2014;312(19):
36 Safety Endpoints 74% of safety events were periprocedural (within 7 days) Reddy, VY et al. JAMA. 2014;312(19):
37 WATCHMAN Clinical Studies 2002 Pilot study, non-randomized 2005 PROTECT AF (WATCHMAN v. warfarin) 2008 CAP registry (continuing access) 2009 ASAP (non-randomized in non-warfarin candidates) 2010 PREVAIL (WATCHMAN v. warfarin, new operators) 2012 CAP2 registry (continuing access) 2013 Asia/EU registry 2014 PREVENT (US Registry) Total ~2,400 patients and 6,000 patient-years of follow-up
38 Left Atrial Appendage Closure Learning Curve 12.0% 10.0% 9.9% PROTECT AF v. PREVAIL Pericardial effusion 4.0% v. 1.4% Periprocedure CVA 1.1% v. 0% Patients with Safety Event (%) 8.0% 6.0% 4.0% 4.8% 4.1% 4.1% 3.8% 2.8% 2.0% 0.0% PROTECT AF CAP PREVAIL CAP2 Ewolution N=232 N=231 N=566 N=269 N=579 1 st Half 2 nd Half N=1019
39 Procedural Complications 5.00% 4.00% 3.00% 2.00% 1.00% 0.00% PROTECT AF (n=463) CAP (n=566) PREVAIL (n=269) CAP2 (n=579) EWOLUTION (n=1021) US Cohort (n=3822) Pericardial Tamponade Procedure-Related Stroke Device Embolization Procedure-Related Death
40 5 year outcomes meta-analysis PROTECT AF/PREVAIL Reddy VY et al. J Am Coll Cardiol Dec 18;70(24):
41 DOACs and Warfarin Ruff et al: Lancet 383: 955, 2014
42 Anticoagulation and stroke reduction Treatment Placebo Stroke Incidence 10.0% 8.0% 6.0% 4.0% 2.0% 2.3% 7.4% 3.6% 6.3% 2.9% 3.1% 2.3% 2.6% 3.0% 2.2% 4.2% 4.5% 5.6% 8.2% 4.4% 3.0% 0.0% SPAF Investigators. Circulation. 1996; Patel MR. NEJM. 2011; Granger CB. NEJM. 2011; Giugliano RP. NEJM
43 Clinical trials of stroke reduction Treatment Placebo 9.0% 8.0% 8.2% 8.2% 7.0% % Stroke 6.0% 5.0% 4.0% 3.0% 5.2% 5.6% 3.0% 4.4% 2.0% 1.0% 0.0% HTN--SHEP LAA closure (3.8 yr f/u) LAA closure (2 yr f/u) 1.1% 1.0% 1.2% Physician's Health Study 1.4% HPS 5y 0.3% 0.7% JUPITER
44 Absolute stroke reduction 6.0% 5.0% 5.1% 4.0% 3.0% 2.7% 3.0% 2.6% 2.0% 1.0% 0.0% 1.4% 0.7% 0.6% 0.5% 0.3% 0.3% 0.2%
45 Hypothetical benefit vs. No Therapy Ischemic Stroke Risk % (Events/100 Patient-Years) Observed WATCHMAN Ischemic Stroke Rate Imputed Ischemic Stroke Rate* PROTECT AF PREVAIL Only CAP Baseline CHA 2 DS 2 -VASc = 3.4 Baseline CHA 2 DS 2 -VASc = 3.8 Baseline CHA 2 DS 2 -VASc = 3.9 * Imputation based on published rate with adjustment for CHA 2 DS 2 -VASc score (3.0); Olesen JB. Thromb Haemost (2011)
46 HAS-BLED Score Risk Factor Score Hypertension (SBP >160) 1 Abnormal renal/liver function 1-2 Stroke 1 Bleeding 1 Labile INR 1 Elderly (>65) 1 Drugs that increase bleeding/alcohol 1-2 Lip et al: Chest 137:263, 2010; Camm AJ et al: Eur Heart J 31:2369, 2010
47 Stroke reduction versus bleeding CHA 2 DS 2 -VASc* Score Annual % Stroke Risk HAS-BLED** Score Annual % Bleed Risk 10-Year Bleeding Risk (%)*** AHA / ACC / HRS Guidelines ** Lip. JACC (2011)
48 HAS-BLED score % Major Bleeding per 100 Patient Years HAS-BLED Observed Major bleeding: hospitalization for >2 unit hgb decrease or hemorrhagic stroke 0 Pisters R. Chest Journal
49 Clinical Practice Difficulty maintaining anticoagulation High bleeding risk Older, frail patients with multiple comorbidities and polypharmacy with bleeding risks Younger patients with long-term, lifetime risk for bleeding CHADS2-VASC 2 and high HAS-BLED 3
50 Patent Foramen Ovale Closure
51 PFO and stroke association PFO present in about 25% of the general population About 40-50% in patients with cryptogenic stroke Meta-analysis of case-control studies evaluating the association of stroke and PFO 2020 control v stroke patients Any stroke OR 1.83 ( ) Cryptogenic stroke OR 2.95 ( ) PFO+ASA OR ( ) Age 55 Overell JR. Neurology (8)
52 Just a hypothesis? 60 yo man with embolic stroke
53 Clergeau, et al. Stroke. 2009;40(12): Kent DM. Neurology. 2013; Aug 13; 81(7): Paradoxical Emboli Right to left shunting of venous thrombus 60 patients with pulmonary emboli 6 patients with acute emboli on MRI 33% of patients with a PFO had emboli (5 of 15) 2.2% of patients without PFO had emboli (1/45) If you had brain emboli, 83% chance you had a PFO ROPE Score RoPE Score Prevalence of PFO 2y Stroke/TIA recurrence 7 54% 6% 8 67% 6% % 2%
54 But is the heart the right target? CLOSURE 1 PC RESPECT CLOSE RESPOND
55 CLOSURE-1 P = 0.37 Stroke or TIA in prior 6 months PFO on TEE Age subjects randomized 1:1 PFO closure with NMT Starflex device Medical therapy with ASA and/or Warfarin PFO Closure Medical Therapy P-value Stroke/TIA/Death 5.5% 6.8% 0.37 Stroke 2.9% 3.1% 0.79 TIA 3.1% 4.1% 0.44 Major vascular compl. 3.2% 0.0% <0.01 Major bleeding 2.6% 1.1% 0.11 Atrial Fibrillation 5.7% 0.7% <0.01 Furlan AJ. NEJM. 2012; 366:
56 PC Trial 414 patients with cryptogenic stroke within 1 year imaging verified Age 60 PFO on TEE PFO Closure Medical Therapy P-value Stroke/TIA/Death 3.4% 5.2% 0.34 Stroke 0.5% 2.4% 0.14 TIA 2.5% 3.3% 0.56 Major bleeding 0.5% 1.4% 0.62 Atrial Fibrillation 2.9% 1.0% 0.17 Meier B. NEJM. 2013; 368:
57 Take and aspirin and call me when you prove it works STEVEN MESSE, MD
58 RESPECT 980 patients with cryptogenic stroke imaging verified Age 60 PFO on TEE PFO Closure Medical Therapy P-value Major bleeding 0.4% 0.4% NS Atrial Fibrillation 0.2% 0.2% NS Carroll J. NEJM. 2013; 368:
59 RESPECT trial: extended outcomes Strokes 3.6% v 5.8% (p 0.046) Saver JL. NEJM. 2017; 377:
60 RESPECT Extended Follow-up Carroll JD. TCT
61 RESPECT Extended Follow-up Carroll JD. TCT
62 REDUCE 664 patients with cryptogenic stroke and PFO Randomized to 2:1 to Helex/Cardioform v. antiplatelet tx Sondergaard L. NEJM. 377:
63 CLOSE trial 663 pts with cryptogenic stroke and PFO with ASA or large shunt PFO closure (open label) v. ASA v. anticoagulation Stroke 0% v. 6.2% v. 1.4% Mas JL. NEJM. 377:
64 PFO Closure: Procedural Complications RESPECT CLOSE REDUCE CLOSURE-1 Stroke 0.4% 0.0% 0.0% 0.7% Atrial fibrillation 0.4% 4.6% 6.6% 5.7% Major Bleeding/Vasc 0.4% 0.8% 0.9% 3.2% Residual shunt 0.4% 5.5% 13.9% Device embolization 0.0% 0.0% 0.5% 0.0% Death/disability 0.0% 0.0% 0.0% 0.0% Furlan AJ. NEJM. 2012; 366: Carroll J. NEJM. 2013; 368: Sondergaard L. NEJM. 377: Mas JL. NEJM. 377:
65 What does this mean? FDA approval we will start seeing these patients Rates of recurrent cryptogenic stroke are low, but Potential benefit for PFO closure: Younger patients Atrial septal aneurysms Large shunts No other risk factors
66 RoPE Score Model derived from 12 studies of cryptogenic stroke Likelihood stroke related to PFO HTN Diabetes Smoker Prior Strokes Age RoPE Score Prevalence of PFO 2y Stroke/TIA recurrence % 20% 4 35% 12% 5 34% 7% 6 47% 8% 7 54% 6% 8 67% 6% % 2% Kent DM. Neurology. 2013; Aug 13; 81(7):
67 Future Directions
68 Heart Brain Teams Collaborative decision making Neurologists Accuracy of diagnosis Likelihood of stroke reduction with LAA/PFO closure Weighing relative benefit of medical v. device Cardiologists Anatomical risk of LAA/PFO Technical feasibility of procedure Evaluation of other cardioembolic sources
69
70 It s Not Like TAVR at All Challenges of Transcatheter Mitral Valve Therapies CREIGHTON W. DON, MD, PHD ASSOCIATE PROFESSOR OF MEDICINE DIRECTOR, INTERVENTIONAL AND STRUCTURAL HEART FELLOWSHIPS DIVISION OF CARDIOLOGY UNIVERSITY OF WASHINGTON
71 Cost Effectiveness Estimates $300 Dollars per Life Year or QALY ($thousands) $250 $200 $150 $100 $50 $0 aspirin MI prevention rosuvastatin high-crp ICD prim prev CRT-D v. medical Rx dabigatran AF PARTNER Cohort B AF ablation vs. AAD dialysis PCI stable CAD LVAD destination Rx
72 Epidemiology United States 1.7% of US population Olmstead County % Moderate to severe disease % Moderate to severe disease Nkomo VT. Et al. Lancet Sep 16;368(9540):
73 Percutaneous Valve Solutions MitraClip Percutaneous Valves TAVR in mitral Tiara (Neovasc), Tendyne, CardiAQ, Twelve
74 Percutaneous Annular Solutions Carillon (Cardiac Dimensions) Cardioband (Valtech) AccuCinch (Ancora Heart) Mitralign
75 Currently Available Therapies at UW High risk surgical patients Therapy MitraClip AccuCinch TIARA TAVR in Mitral Hybrid Surgical TAVR in Mitral Valvuloplasty Ideal patient Functional and degenerative MR with appropriate leaflet anatomy Functional MR Mitral regurgitation with appropriately sized annulus Mitral stenosis or mixed MR/MS Significant annular/leaflet calcification Moderate calcification Unfavorable LVOT-aortic-mitral relationship Rheumatic mitral stenosis without significant calcification
76 UW Clinical trials MITRAL AccuCinch TIARA
77 MITRAL Phase 1 study--calcific native mitral valve with annular calcification 90 patients with moderate-severe stenosis NYHA 2-4 Very high risk for surgery Outcomes Technical/procedural success Safety/MACE Mitral Regurg/PVL NYHA class, KCCQ, 6 min walk time, rehospitalizations
78 AccuCinch Phase I feasibility study 15 patients with moderate-severe FMR NYHA 2-4 High risk surgical candidate Outcomes Procedural/Technical success Safety at 1, 12 mo Hospitalizations, 6 min walk, QOL, NYHA class
79 TIARA Phase 1 study of patients 30 patients with severe mitral regurgitation High risk for surgery NYHA Class 2-4 Appropriate anatomy Outcomes Device success Mortality, stroke, MI, reintervention 1, 3, 6, 12 months Heart failure NYHA class, 6 min walk time, KCCQ
80 Tricuspid regurgitation Trialign
81 Tricuspid Valve
82 Tricuspid Valve Stenosis
83 Thank You Creighton Don (pager) Structural heart VALV (8258) Other interventional
Left Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationGauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
More informationAtrial Fibrillation. Atrial Fibrillation
Atrial Fibrillation Stroke and Blood Thinning Medications What else is available? Srinivas Iyengar, MD, FACC, with Boulder Heart Structural Heart Director, Boulder Community Health 303-622-5849 Atrial
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationLive in a Box: Left Atrial Appendage Closure Device
Live in a Box: Left Atrial Appendage Closure Device Fayez Bokhari, MD, FRCPC KFAFH, Jeddah Saudi Arabia Joint Saudi Heart Association/SACIS April 18, 2015 News: Interventional Cardiologists harm patients
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationAn Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman
An Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman Yakima Valley Medical Conference Moses Mathur MD MSc March 2018 Outline CC : 85 yo M w/ Shortness of breath TTE : Cardiomyopathy
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationLEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES. Sheetal Chandhok, MD
LEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES Sheetal Chandhok, MD Disclosures Boston Scientific: Speaker (Watchman) Trainer (Watchman) SentreHeart Primary Investigator
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationNEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION
NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION MAY 1, 2015 Melissa R. Robinson, MD FACC FHRS CCDS Assistant Professor of Medicine Director of the Complex Arrhythmia Service POINTS TO MAKE
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationAntithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationCryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationManaging the Left Atrial Appendage: Concepts & Controversies
Managing the Left Atrial Appendage: Concepts & Controversies SH-102103-AD- APR 2013 Carlos A. Morillo, MD, FRCPC, FACC, FHRS, FESC Professor Department of Cardiac Sciences Section Chief Cardiology Division,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationPatient with high risk for bleeding
Will Apixaban change practice in atrial fibrillation Luncheon Satellite Sponsored by Pfizer Patient with high risk for bleeding Prof. Amos Katz M.D August 2012: patient background 67-year-old woman History
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationLeft Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP
Left Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP Cardiac Electrophysiology Nurse Practitioner OhioHealth Heart & Vascular Physicians Riverside Methodist Hospital none Disclosures Atrial Fibrillation
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationStroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow
Stroke Case Studies Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Case 1 64 year old female with dysphasia and right arm weakness 3 hours prior CT head: dense M1 sign. No established ischaemia
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationLeft Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationStroke Update. Claire J. Creutzfeldt, MD January 12, 2018
Stroke Update Claire J. Creutzfeldt, MD January 12, 2018 Disclosures None relevant to this presentation I receive funding from the NINDS What s new in stroke? A new model for cardioembolic stroke: atrial
More informationManagement of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018
Management of Atrial Fibrillation Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018 Disclosures Speaker: St. Jude Medical, Biotronik Consultant: St. Jude Medical, World Care Clinical Objectives Recognize
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationPapel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico
Imagiologia na Fibrilhac ão Auricular Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Mª João Andrade Diagnosis and timely detection of atrial fibrillation Echo-machines
More informationPFO Management update
PFO Management update May 12, 2017 Peter Casterella, MD Swedish Heart and Vascular 1 PFO Update 2017: Objectives Review recently released late outcomes of RESPECT trial and subsequent FDA approval of PFO
More informationPatent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More information(LAA Closure & PFO Closure)
18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Review Year and Future To Closure or Not to Close (LAA Closure & PFO Closure) Horst Sievert CardioVascular Center Frankfurt - CVC Frankfurt,
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationUpdates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
More informationEAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationRahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationCryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare
Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation
More informationRisk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers
Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Banff 2013 CP1221547-8 Meta-Analysis of Stroke 5 Randomized Trials Placebo Stroke Rate 4.5%/yr
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationUpdate in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More informationI, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationControversies in Risk Stratification
Controversies in Risk Stratification There are more questions than answers So---Let me pose the questions Banff 2016 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of
More informationTrue cryptogenic stroke
True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More information